Aura Biosciences (AURA) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OmniAb (OABI) has outperformed Aura Biosciences (AURA) over the past year, gaining 166.3% versus a gain of 6.8%. OmniAb is the larger company by market cap ($697.1 million vs $686.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | OABI |
|---|---|---|
| Share price | $6.62 | $4.80 |
| Market cap | $686.53M | $697.15M |
| 1-day change | +1.77% | +2.90% |
| YTD return | +19.36% | +151.89% |
| 1-year return | +6.81% | +166.29% |
| 5-year return | — | -53.26% |
| EPS (TTM) | $-1.75 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $5.43 |
| 52-week low | $4.73 | $1.30 |
| Distance from 52-week high | -30.57% | -11.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +150.76% | +73.72% |
| Average volume | 756.20K | 1.47M |
| Shares outstanding | 103.70M | 145.39M |
| Employees | 113 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed AURA by 159.5 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
AURA vs OABI FAQ
Which is bigger, Aura Biosciences or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $697.15M compared with $686.53M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or OABI?
OABI returned +166.29% over the past 12 months, compared with +6.81% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Aura Biosciences and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.